An­oth­er one of Bob Langer's MIT post­docs scores a biotech deal, auc­tion­ing his start­up for up to $415M

An­oth­er one of Bob Langer’s for­mer post­docs has scored a win in the biotech field.

Bryan Laulicht has struck a deal to sell a lit­tle biotech he built up to AM­AG Phar­ma­ceu­ti­cals, which likes the late-stage an­ti­co­ag­u­lant re­ver­sal agent he has been de­vel­op­ing with the team at Per­os­phere Phar­ma­ceu­ti­cals.

AM­AG is pay­ing $50 mil­lion in cash to buy the com­pa­ny while as­sum­ing $18.2 mil­lion in debt and li­a­bil­i­ties. There’s $140 mil­lion in reg­u­la­to­ry mile­stones on the ta­ble, with a lump sum pay­out for an FDA ap­proval with­out a black box warn­ing as well as $40 mil­lion for an EMA OK. An­oth­er $225 mil­lion is built in for sales goals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER